ID

37842

Beschreibung

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE); ODM derived from: https://clinicaltrials.gov/show/NCT01120184

Link

https://clinicaltrials.gov/show/NCT01120184

Stichworte

Versionen (1)
  1. 27.08.19 27.08.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

27. August 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT01120184

Englisch

Eligibility Breast Cancer NCT01120184

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients >/=18 years of age
Beschreibung

Adult | Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
her2-positive breast cancer
Beschreibung

HER2-positive carcinoma of breast

Datentyp

boolean

Alias
UMLS CUI [1]
C1960398
histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. patients with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.
Beschreibung

Breast adenocarcinoma recurrent Locally | Breast adenocarcinoma metastatic | Patients Appropriate Chemotherapy | Recurrent disease Advanced Locally | Progressive Disease Advanced Locally | Excision Curative intent Unsuccessful

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0861355
UMLS CUI [1,2]
C1517927
UMLS CUI [2]
C1697918
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C1548787
UMLS CUI [3,3]
C0392920
UMLS CUI [4,1]
C0277556
UMLS CUI [4,2]
C0205179
UMLS CUI [4,3]
C1517927
UMLS CUI [5,1]
C1335499
UMLS CUI [5,2]
C0205179
UMLS CUI [5,3]
C1517927
UMLS CUI [6,1]
C0728940
UMLS CUI [6,2]
C1276305
UMLS CUI [6,3]
C1272705
patients must have measurable and/or non-measurable disease which must be evaluable per recist 1.1
Beschreibung

Measurable Disease | Non-Measurable Lesion | Evaluable Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2]
C1334988
UMLS CUI [3]
C1516986
ecog performance status 0 or 1
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
adequate organ function as determined by laboratory results
Beschreibung

Organ function Laboratory Results

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0678852
UMLS CUI [1,2]
C1254595
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of prior (or any) chemotherapy for metastatic breast cancer or recurrent locally advanced disease
Beschreibung

Prior Chemotherapy Secondary malignant neoplasm of female breast | Chemotherapy Secondary malignant neoplasm of female breast | Prior Chemotherapy Recurrent disease Advanced Locally | Chemotherapy Recurrent disease Advanced Locally

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0346993
UMLS CUI [2,1]
C0392920
UMLS CUI [2,2]
C0346993
UMLS CUI [3,1]
C1514457
UMLS CUI [3,2]
C0277556
UMLS CUI [3,3]
C0205179
UMLS CUI [3,4]
C1517927
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C0277556
UMLS CUI [4,3]
C0205179
UMLS CUI [4,4]
C1517927
an interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic chemotherapy until the time of metastatic diagnosis
Beschreibung

Vinca Alkaloid Cytotoxic Chemotherapy | Taxane Cytotoxic Chemotherapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0042672
UMLS CUI [1,2]
C0677881
UMLS CUI [2,1]
C0215136
UMLS CUI [2,2]
C0677881
hormone therapy <7 days prior to randomization
Beschreibung

Hormone Therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0279025
trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to randomization
Beschreibung

Trastuzumab Neoadjuvant Therapy | Lapatinib Neoadjuvant Therapy | Trastuzumab Adjuvant therapy | Lapatinib Adjuvant therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C0600558
UMLS CUI [2,1]
C1506770
UMLS CUI [2,2]
C0600558
UMLS CUI [3,1]
C0728747
UMLS CUI [3,2]
C0677850
UMLS CUI [4,1]
C1506770
UMLS CUI [4,2]
C0677850
prior trastuzumab emtansine or pertuzumab therapy
Beschreibung

trastuzumab emtansine | pertuzumab

Datentyp

boolean

Alias
UMLS CUI [1]
C2935436
UMLS CUI [2]
C1328025
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Breast Cancer NCT01120184

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients >/=18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
HER2-positive carcinoma of breast
Item
her2-positive breast cancer
boolean
C1960398 (UMLS CUI [1])
Breast adenocarcinoma recurrent Locally | Breast adenocarcinoma metastatic | Patients Appropriate Chemotherapy | Recurrent disease Advanced Locally | Progressive Disease Advanced Locally | Excision Curative intent Unsuccessful
Item
histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. patients with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.
boolean
C0861355 (UMLS CUI [1,1])
C1517927 (UMLS CUI [1,2])
C1697918 (UMLS CUI [2])
C0030705 (UMLS CUI [3,1])
C1548787 (UMLS CUI [3,2])
C0392920 (UMLS CUI [3,3])
C0277556 (UMLS CUI [4,1])
C0205179 (UMLS CUI [4,2])
C1517927 (UMLS CUI [4,3])
C1335499 (UMLS CUI [5,1])
C0205179 (UMLS CUI [5,2])
C1517927 (UMLS CUI [5,3])
C0728940 (UMLS CUI [6,1])
C1276305 (UMLS CUI [6,2])
C1272705 (UMLS CUI [6,3])
Measurable Disease | Non-Measurable Lesion | Evaluable Disease
Item
patients must have measurable and/or non-measurable disease which must be evaluable per recist 1.1
boolean
C1513041 (UMLS CUI [1])
C1334988 (UMLS CUI [2])
C1516986 (UMLS CUI [3])
ECOG performance status
Item
ecog performance status 0 or 1
boolean
C1520224 (UMLS CUI [1])
Organ function Laboratory Results
Item
adequate organ function as determined by laboratory results
boolean
C0678852 (UMLS CUI [1,1])
C1254595 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Prior Chemotherapy Secondary malignant neoplasm of female breast | Chemotherapy Secondary malignant neoplasm of female breast | Prior Chemotherapy Recurrent disease Advanced Locally | Chemotherapy Recurrent disease Advanced Locally
Item
history of prior (or any) chemotherapy for metastatic breast cancer or recurrent locally advanced disease
boolean
C1514457 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
C1514457 (UMLS CUI [3,1])
C0277556 (UMLS CUI [3,2])
C0205179 (UMLS CUI [3,3])
C1517927 (UMLS CUI [3,4])
C0392920 (UMLS CUI [4,1])
C0277556 (UMLS CUI [4,2])
C0205179 (UMLS CUI [4,3])
C1517927 (UMLS CUI [4,4])
Vinca Alkaloid Cytotoxic Chemotherapy | Taxane Cytotoxic Chemotherapy
Item
an interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic chemotherapy until the time of metastatic diagnosis
boolean
C0042672 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C0215136 (UMLS CUI [2,1])
C0677881 (UMLS CUI [2,2])
Hormone Therapy
Item
hormone therapy <7 days prior to randomization
boolean
C0279025 (UMLS CUI [1])
Trastuzumab Neoadjuvant Therapy | Lapatinib Neoadjuvant Therapy | Trastuzumab Adjuvant therapy | Lapatinib Adjuvant therapy
Item
trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to randomization
boolean
C0728747 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C1506770 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C0728747 (UMLS CUI [3,1])
C0677850 (UMLS CUI [3,2])
C1506770 (UMLS CUI [4,1])
C0677850 (UMLS CUI [4,2])
trastuzumab emtansine | pertuzumab
Item
prior trastuzumab emtansine or pertuzumab therapy
boolean
C2935436 (UMLS CUI [1])
C1328025 (UMLS CUI [2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video